Akathisia vs tardive dyskinesia: early restlessness vs late involuntary movement

The deciding difference: felt urge vs unnoticed movement

The single best discriminator is the client's experience. Akathisia has a subjective part, an inner tension and inability to sit still, and an objective part, such as crossing and uncrossing legs, shifting from foot to foot or pacing. Clients often describe it as nervousness or feeling like they want to jump out of their skin, and MSD Manuals calls it particularly unpleasant.

Tardive dyskinesia is involuntary and often not distressing to the person who has it. MSD describes puckering of the lips and tongue, finger movements and writhing of the arms or legs. Others may notice the movements before the client does. The client does not report an urge to move; the movements simply happen.

Timing, reversibility and screening scales

A review of akathisia in PubMed Central places acute akathisia within days to weeks of starting an antipsychotic or increasing the dose. Tardive dyskinesia is a late effect: with first-generation antipsychotics, MSD estimates the risk rises by about 5 percent with each year of exposure, and it is considerably lower with second-generation drugs.

Reversibility differs too. Akathisia usually improves with dose reduction or a switch. MSD notes that in some patients tardive dyskinesia persists indefinitely, even after the medication is stopped. Each has its own scale: the Barnes Akathisia Rating Scale for akathisia, and the Abnormal Involuntary Movement Scale (AIMS) for tardive dyskinesia, which MSD advises using at least every 6 months during maintenance therapy.

MSD describes tardive dyskinesia risk as cumulative, so a newer drug with a lower risk is not a reason to skip the AIMS check at follow-up visits. The scales also work as a pair in practice: a client with new pacing after a dose increase calls for the Barnes scale, while a client with years of exposure and new tongue movements calls for AIMS.

Why mislabeling akathisia as agitation is dangerous

The PubMed Central review warns that akathisia is often mistaken for anxiety or worsening psychotic agitation. If the team responds by raising the antipsychotic dose, the akathisia gets worse. Increasing severity of akathisia has been linked to new or worsening suicidal thoughts, aggression and violence, and MSD notes it may lead clients to stop taking their medication.

So when a client recently started on an antipsychotic becomes restless, the nurse asks what the restlessness feels like and when it began, documents it objectively, and reports it as a possible adverse effect. Treatment options listed by MSD and the review include lowering the dose or switching drugs, propranolol, and benzodiazepines, all under prescriber direction.

Hypothetical practice scenario

Hypothetical scenario, not a real exam item: a client started on haloperidol five days ago paces the hallway, cannot sit through group, and says, "I feel like I have to keep moving, it's driving me crazy." A staff member says the client is escalating and asks for a PRN dose of the same antipsychotic. What should the nurse do first?

Assess for akathisia and report it before treating it as agitation. Giving more of the drug that caused the restlessness is the trap here, since it can worsen the problem. Tardive dyskinesia is unlikely after five days and would not come with a described urge to move. Acute dystonia would show sustained muscle spasms, not pacing.

Sources and further reading

MSD Manual Professional Version: Antipsychotic Medications. Akathisia as an unpleasant extrapyramidal effect that may cause nonadherence and its treatments; TD features, 5 percent per year risk, persistence after stopping, AIMS every 6 months, valbenazine and deutetrabenazine.

Akathisia review, PubMed Central (PMC5771055). Subjective and objective components, acute onset within days to weeks, misidentification as anxiety or agitation, worsening with dose escalation, link to suicidal ideation and aggression, Barnes Akathisia Rating Scale, first-line dose reduction.